Iatrogenic osteomalacia in epileptic children. A controlled therapeutic trial.
Bone mineral content (BMC) ub tge forearms (related to total body calcium) was measured for a controlled therapeutic trial in 25 epileptic children on long-term treatment with phenytoin and in 22 normal children before and during treatment with vitamin D or placebo. In the epileptic children, hypocalcaemia and elevated serum alkaline phosphatase was found in 20% and 16%, respectively. The group of epileptic children treated with vitamin D2 (2000 IU daily) for 3 months showed a significant increase in bone mineral content, 5% on average. The epileptic children treated with placebo showed a significant decrease, 2% on average, while the normal children treated with vitamin D or placebo showed no change in bone mineral content. The results indicate a possible benefit of prophylactic vitamin D treatment in epileptic children.
D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D004827:Epilepsy / Q000188:drug therapy*; D010018:Osteomalacia / Q000139:chemically induced / Q000517:prevention & control*; D010672:Phenytoin / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011884:Radius / Q000187:drug effects / Q000378:metabolism; D013268:Stimulation, Chemical; D014457:Ulna / Q000187:drug effects / Q000378:metabolism; D014807:Vitamin D / Q000494:pharmacology / Q000627:therapeutic use*
D010919:Placebos; D014807:Vitamin D; D010672:Phenytoin; D002118:Calcium